Vascular endothelial growth factor family of ligands and receptors: Review

Blood Cells, Molecules, and Diseases

Volumn 38, Issue 3, 2007, Pages 258-268

  Otrock, Zaher K ^a   Makarem, Jawad A ^a   Shamseddine, Ali I ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Angiogenesis; Ligand; Receptor; Review; Vascular endothelial growth factor

Indexed keywords

NEUROPILIN 1; NEUROPILIN 2; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN F; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANGIOGENESIS; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; LIGANDS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 34047141776     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2006.12.003     Document Type: Review

References (143)

1. Risau W. Mechanisms of angiogenesis. Nature 386 (1997) 671-674
2. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev., Cancer 2 (2002) 795-803
3. Gupta K., and Zhang J. Angiogenesis: a curse or cure?. Postgrad. Med. J. 81 (2005) 236-242
4. Ferrara N., Gerber H.P., and LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9 (2003) 669-676
5. Houck K.A., Ferrara N., Winer J., et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 5 (1991) 1806-1814
6. Suto K., Yamazaki Y., Morita T., et al. Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1. J. Biol. Chem. 280 (2005) 2126-2131
7. Senger D.R., Galli S.J., Dvorak A.M., et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219 (1983) 983-985
8. Rini B.I., and Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 23 (2005) 1028-1043
9. Leung D.W., Cachianes G., Kuang W.J., et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246 (1989) 1306-1309
10. Tischer E., Mitchell R., Hartman T., Silva M., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266 (1991) 11947-11954
11. Neufeld G., Cohen T., Gengrinovitch S., and Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13 (1999) 9-22
12. Sheen I.S., Jeng K.S., Shih S.C., et al. Clinical significance of the expression of isoform 165 vascular endothelial growth factor mRNA in noncancerous liver remnants of patients with hepatocellular carcinoma. World J. Gastroenterol. 11 (2005) 187-192
13. Nishi M., Abe Y., Tomii Y., et al. Cell binding isoforms of vascular endothelial growth factor-A (VEGF189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma. Int. J. Oncol. 26 (2005) 1517-1524
14. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20 (2002) 4368-4380
15. Cross M.J., Dixelius J., Matsumoto T., and Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem. Sci. 28 (2003) 488-494
16. Benjamin L.E., and Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 8761-8766
17. Gerber H.P., Dixit V., and Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 273 (1998) 13313-13316
18. Hood J.D., Meininger C.J., Ziche M., and Granger H.J. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am. J. Physiol. 274 (1998) H1054-H1058
19. Storkebaum E., Lambrechts D., and Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. BioEssays 26 (2004) 943-954
20. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25 (2004) 581-611
21. Jakeman L.B., Armanini M., Phillips H.S., and Ferrara N. Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 133 (1993) 848-859
22. Shweiki D., Itin A., Neufeld G., et al. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J. Clin. Invest. 91 (1993) 2235-2243
23. Carmeliet P., Ferreira V., Breier G., et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380 (1996) 435-439
24. Brown L.F., Yeo K.T., Berse B., et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J. Exp. Med. 176 (1992) 1375-1379
25. Xia Y.P., Li B., Hylton D., et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 102 (2003) 161-168
26. Larcher F., Murillas R., Bolontrade M., et al. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 17 (1998) 303-311
27. Rossiter H., Barresi C., Pammer J., et al. Loss of vascular endothelial growth factor A activity in murine epidermal keratinocytes delays wound healing and inhibits tumor formation. Cancer Res. 64 (2004) 3508-3516
28. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29 (2002) 10-14
29. Grimmond S., Lagercrantz J., Drinkwater C., et al. Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res. 6 (1996) 124-131
30. Paavonen K., Horelli-Kuitunen N., Chilov D., et al. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. Circulation 93 (1996) 1079-1082
31. Silins G., Grimmond S., Egerton M., et al. Analysis of the promoter region of the human VEGF-related factor gene. Biochem. Biophys. Res. Commun. 230 (1997) 413-418
32. Ristimaki A., Narko K., Enholm B., et al. Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J. Biol. Chem. 273 (1998) 8413-8418
33. Asano A., Kimura K., and Saito M. Cold-induced mRNA expression of angiogenic factors in rat brown adipose tissue. J. Vet. Med. Sci. 61 (1999) 403-409
34. Nash A.D., Baca M., Wright C., et al. The biology of vascular endothelial growth factor-B (VEGF-B). Pulm. Pharmacol. Ther. 19 (2006) 61-69
35. Scotney P.D., MacKenzie A., Maccarone P., et al. Human vascular endothelial growth factor B: characterization of recombinant isoforms and generation of neutralizing monoclonal antibodies. Clin. Exp. Pharmacol. Physiol. 29 (2002) 1024-1029
36. Christinger H.W., Fuh G., de Vos A.M., and Wiesmann C. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J. Biol. Chem. 279 (2004) 10382-10388
37. Wiesmann C., Fuh G., Christinger H.W., et al. Crystal structure at 1.7 Å resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell 91 (1997) 695-704
38. Olofsson B., Pajusola K., Kaipainen A., et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 2576-2581
39. Olofsson B., Pajusola K., von Euler G., et al. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J. Biol. Chem. 271 (1996) 19310-19317
40. Enholm B., Paavonen K., Ristimaki A., et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14 (1997) 2475-2483
41. Salven P., Lymboussaki A., Heikkila P., et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am. J. Pathol. 153 (1998) 103-108
42. Bellomo D., Headrick J.P., Silins G.U., et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ. Res. 86 (2000) E29-E35
43. Mould A.W., Tonks I.D., Cahill M.M., et al. Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum. 48 (2003) 2660-2669
44. Abraham D., Hofbauer R., Schafer R., et al. Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ. Res. 87 (2000) 644-647
45. Silvestre J.S., Tamarat R., Ebrahimian T.G., et al. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ. Res. 93 (2003) 114-123
46. Kawakami M., Furuhata T., Kimura Y., et al. Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer. J. Exp. Clin. Cancer Res. 22 (2003) 229-237
47. Joukov V., Sorsa T., Kumar V., et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16 (1997) 3898-3911
48. Siegfried G., Basak A., Cromlish J.A., et al. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J. Clin. Invest. 111 (2003) 1723-1732
49. Saharinen P., Tammela T., Karkkainen M.J., and Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol. 25 (2004) 387-395
50. Karkkainen M.J., Haiko P., Sainio K., et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5 (2004) 74-80
51. Kukk E., Lymboussaki A., Taira S., et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122 (1996) 3829-3837
52. Schoppmann S.F., Birner P., Stockl J., et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 161 (2002) 947-956
53. Skobe M., Hamberg L.M., Hawighorst T., et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am. J. Pathol. 59 (2001) 893-903
54. Lymboussaki A., Olofsson B., Eriksson U., and Alitalo K. Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia. Circ. Res. 85 (1999) 992-999
55. Jeltsch M., Kaipainen A., Joukov V., et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276 (1997) 1423-1425
56. Saaristo A., Veikkola T., Enholm B., et al. Adenoviral VEGF-C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes. FASEB J. 16 (2002) 1041-1049
57. Enholm B., Karpanen T., Jeltsch M., et al. Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ. Res. 88 (2001) 623-629
58. Chilov D., Kukk E., Taira S., et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J. Biol. Chem. 272 (1997) 25176-25183
59. Neufeld G., Tessler S., Gitay-Goren H., et al. Vascular endothelial growth factor and its receptors. Prog. Growth Factor Res. 5 (1994) 89-97
60. Mandriota S.J., Jussila L., Jeltsch M., et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20 (2001) 672-682
61. Liu J., Yu H.G., Yu J.P., et al. Overexpression of cyclooxygenase-2 in gastric cancer correlates with the high abundance of vascular endothelial growth factor-C and lymphatic metastasis. Med. Oncol. 22 (2005) 389-398
62. Hachisuka T., Narikiyo M., Yamada Y., et al. High lymphatic vessel density correlates with overexpression of VEGF-C in gastric cancer. Oncol. Rep. 13 (2005) 733-737
63. Fujimoto J., Toyoki H., Sato E., et al. Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers. Br. J. Cancer 91 (2004) 466-469
64. He Y., Karpanen T., and Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim. Biophys. Acta 1654 (2004) 3-12
65. Farnebo F., Piehl F., and Lagercrantz J. Restricted expression pattern of vegf-d in the adult and fetal mouse: high expression in the embryonic lung. Biochem. Biophys. Res. Commun. 257 (1999) 891-894
66. Akahane M., Akahane T., Matheny S.L., et al. Vascular endothelial growth factor-D is a survival factor for human breast carcinoma cells. Int. J. Cancer 118 (2006) 841-849
67. Nilsson I., Rolny C., Wu Y., et al. Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development. FASEB J. 18 (2004) 1507-1515
68. Rissanen T.T., Markkanen J.E., Gruchala M., et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ. Res. 92 (2003) 1098-1106
69. Byzova T.V., Goldman C.K., Jankau J., et al. Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo. Blood 99 (2002) 4434-4442
70. Stacker S.A., Caesar C., Baldwin M.E., et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7 (2001) 186-191
71. Achen M.G., Williams R.A., Minekus M.P., et al. Localization of vascular endothelial growth factor-D in malignant melanoma suggests a role in tumour angiogenesis. J. Pathol. 193 (2001) 147-154
72. Von Marschall Z., Scholz A., Stacker S.A., et al. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. Int. J. Oncol. 27 (2005) 669-679
73. Kleespies A., Bruns C.J., and Jauch K.W. Clinical significance of VEGF-A, -C and -D expression in esophageal malignancies. Onkologie 28 (2005) 281-288
74. Ishii H., Yazawa T., Sato H., et al. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer 45 (2004) 325-337
75. Lyttle D.J., Fraser K.M., Fleming S.B., et al. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J. Virol. 68 (1994) 84-92
76. Ogawa S., Oku A., Sawano A., et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 273 (1998) 31273-31282
77. Meyer M., Clauss M., Lepple-Wienhues A., et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18 (1999) 363-374
78. Wise L.M., Veikkola T., Mercer A.A., et al. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 3071-3076
79. NZ-7, is essential for the activation of VEGFR-2 signaling. J. Biol. Chem. 278 (2003) 13453-13461
80. Persico M.G., Vincenti V., and DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). In: Claesson-Welsh L. (Ed). Vascular Growth Factors and Angiogenesis (1999), Springer-Verlag, Berlin 31-40
81. Autiero M., Waltenberger J., Communi D., et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 9 (2003) 936-943
82. Park J.E., Chen H.H., Winer J., et al. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. Biol. Chem. 269 (1994) 25646-25654
83. Nagy J.A., Dvorak A.M., and Dvorak H.F. VEGF-A(164/165) and PlGF: roles in angiogenesis and arteriogenesis. Trends Cardiovasc. Med. 13 (2003) 169-175
84. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med. 7 (2001) 575-583
85. Odorisio T., Schietroma C., Zaccaria M.L., et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability. J. Cell Sci. 115 (2002) 2559-2567
86. Oura H., Bertoncini J., Velasco P., et al. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood 101 (2003) 560-567
87. Wei S.C., Tsao P.N., Yu S.C., et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer. Gut 54 (2005) 666-672
88. Ikai T., Miwa H., Shikami M., et al. Placenta growth factor stimulates the growth of Philadelphia chromosome positive acute lymphoblastic leukemia cells by both autocrine and paracrine pathways. Eur. J. Haematol. 75 (2005) 273-279
89. Dalal S., Berry A.M., Cullinane C.J., et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin. Cancer Res. 11 (2005) 2364-2378
90. Yamazaki Y., Tokunaga Y., Takani K., et al. Identification of the heparin-binding region of snake venom vascular endothelial growth factor (VEGF-F) and its blocking of VEGF-A165. Biochemistry 44 (2005) 8858-8864
91. Shibuya M., Yamaguchi S., Yamane A., et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5 (1990) 519-524
92. Peters K.G., De Vries C., and Williams L.T. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 8915-8919
93. Fong G.H., Rossant J., Gertsenstein M., and Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376 (1995) 66-70
94. Zachary I., and Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc. Res. 49 (2001) 568-581
95. Gerber H.P., Condorelli F., Park J., and Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem. 272 (1997) 23659-23667
96. Barleon B., Sozzani S., Zhou D., et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87 (1996) 3336-3343
97. Clauss M., Weich H., Breier G., et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 271 (1996) 17629-17634
98. Lyden D., Hattori K., Dias S., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7 (2001) 1194-1201
99. Chen W.S., Kitson R.P., and Goldfarb R.H. Modulation of human NK cell lines by vascular endothelial growth factor and receptor VEGFR-1 (FLT-1). In Vivo 16 (2002) 439-445
100. LeCouter J., Moritz D.R., Li B., et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 299 (2003) 890-893
101. Selvaraj S.K., Giri R.K., Perelman N., et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 102 (2003) 1515-1524
102. Hattori K., Heissig B., Wu Y., et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med. 8 (2002) 841-849
103. Luttun A., Tjwa M., Moons L., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8 (2002) 831-840
104. Pipp F., Heil M., Issbrucker K., et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ. Res. 92 (2003) 378-385
105. Kendall R.L., and Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 10705-10709
106. Lamszus K., Ulbricht U., Matschke J., et al. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in astrocytic tumors and its relation to malignancy, vascularity, and VEGF-A. Clin. Cancer Res. 9 (2003) 1399-1405
107. Toi M., Bando H., Ogawa T., et al. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int. J. Cancer 98 (2002) 14-18
108. Terman B.I., Carrion M.E., Kovacs E., et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 6 (1991) 1677-1683
109. Matthews W., Jordan C.T., Gavin M., et al. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 9026-9030
110. Millauer B., Wizigmann-Voos S., Schnurch H., et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72 (1993) 835-846
111. Takahashi T., and Shibuya M. The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 14 (1997) 2079-2089
112. Matsumoto T., and Claesson-Welsh L. VEGF receptor signal transduction. Sci. STKE 2001 (2001) RE21
113. Takahashi T., Yamaguchi S., Chida K., and Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J. 20 (2001) 2768-2778
114. Partanen T.A., Alitalo K., and Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 86 (1999) 2406-2412
115. Baffert F., Thurston G., Rochon-Duck M., et al. Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circ. Res. 94 (2004) 984-992
116. Kabrun N., Buhring H.J., Choi K., et al. Flk-1 expression defines a population of early embryonic hematopoietic precursors. Development 124 (1997) 2039-2048
117. Gille H., Kowalski J., Li B., et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 276 (2001) 3222-3230
118. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273 (1998) 30336-30343
119. Vosseler S., Mirancea N., Bohlen P., et al. Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res. 65 (2005) 1294-1305
120. Li J., Huang S., Armstrong E.A., et al. Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int. J. Radiat. Oncol. Biol. Phys. 62 (2005) 1477-1485
121. Pajusola K., Aprelikova O., Pelicci G., et al. Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene 9 (1994) 3545-3555
122. Hughes D.C. Alternative splicing of the human VEGFGR-3/FLT4 gene as a consequence of an integrated human endogenous retrovirus. J. Mol. Evol. 53 (2001) 77-79
123. Veikkola T., Lohela M., Ikenberg K., et al. Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. FASEB J. 17 (2003) 2006-2013
124. Karkkainen M.J., Ferrell R.E., Lawrence E.C., et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat. Genet. 25 (2000) 153-159
125. Karkkainen M.J., Saaristo A., Jussila L., et al. A model for gene therapy of human hereditary lymphedema. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 12677-12682
126. Chen L., Hamrah P., Cursiefen C., et al. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity. Nat. Med. 10 (2004) 813-815
127. Paavonen K., Puolakkainen P., Jussila L., et al. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol. 156 (2000) 1499-1504
128. Jennbacken K., Vallbo C., Wang W., and Damber J.E. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 65 (2005) 110-116
129. Valtola R., Salven P., Heikkila P., et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J. Pathol. 154 (1999) 1381-1390
130. He Y., Rajantie I., Pajusola K., et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 65 (2005) 4739-4746
131. Miao H.Q., and Klagsbrun M. Neuropilin is a mediator of angiogenesis. Cancer Metastasis Rev. 19 (2000) 29-37
132. Fuh G., Garcia K.C., and de Vos A.M. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor flt-1. J. Biol. Chem. 275 (2000) 26690-26695
133. Bagri A., and Tessier-Lavigne M. Neuropilins as Semaphorin receptors: in vivo functions in neuronal cell migration and axon guidance. Adv. Exp. Med. Biol. 515 (2002) 13-31
134. Kitsukawa T., Shimono A., Kawakami A., et al. Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 121 (1995) 4309-4318
135. Soker S., Takashima S., Miao H.Q., et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92 (1998) 735-745
136. Tordjman R., Ortega N., Coulombel L., et al. Neuropilin-1 is expressed on bone marrow stromal cells: a novel interaction with hematopoietic cells?. Blood 94 (1999) 2301-2309
137. Klagsbrun M., Takashima S., and Mamluk R. The role of neuropilin in vascular and tumor biology. Adv. Exp. Med. Biol. 515 (2002) 33-48
138. Bielenberg D.R., Pettaway C.A., Takashima S., et al. Neuropilins in neoplasms: expression, regulation, and function. Exp. Cell Res. 312 (2006) 584-593
139. Klagsbrun M., and Folkman J. Angiogenesis. In: Sporn M.B., and Roberts A.B. (Eds). Peptide Growth Factors and their Receptors (1991), Springer-Verlag, New York 549-586
140. Herzog Y., Kalcheim C., Kahane N., et al. Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech. Dev. 109 (2001) 115-119
141. Yuan L., Moyon D., Pardanaud L., et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 129 (2002) 4797-4806
142. Kawasaki T., Kitsukawa T., Bekku Y., et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 126 (1999) 4895-4902
143. Gagnon M.L., Bielenberg D.R., Gechtman Z., et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2573-2578